This P30 Cystic Fibrosis (CF) Research and Translational Core Center (CFRTC) is located at the University of Washington School of Medicine (UWSOM) and its affiliated institution, Seattle Children's Research Institute (SCRI). This proposed P30 center program enhances an existing robust basic and clinical research base at these institutions totally over $20 million direct costs in current research funding and an additional $5 million in CF related infrastructure funding, and includes 48 UWSOM investigators in 19 departments and/or divisions. The UWSOM has a long history of excellence in CF related translational research as evidenced by the successful development of inhaled tobramycin (TOBI(r)) and the leadership in the CFF supported Therapeutics Development Network. The research for this P30 will focus on four Specific Aims: 1) Provide resources and expertise to expedite development of promising new therapeutic approaches to correct dysfunctional CFTR and its secondary consequences including maldigestion and malnutrition, hepatobiliary disease and chronic lung disease. 2) Foster collaboration across P-30 biomedical cores, nationally and internationally to enhance translational research through sharing of human and bacterial repositories linked to clinical databases. Utilize these shared specimen and data resources to develop improved assays, biomarkers and clinical outcome measures. 3) Enhance understanding of the evolving bacterial ecosystems and resultant host response in the gastrointestinal and respiratory tracts of patients with cystic fibrosis and how these interactions impact health. 4) Better understand the metabolic and inflammatory consequences of CFTR dysfunction. The center will be led by Co-PD's, Bonnie Ramsey, MD and E. Peter Greenberg PhD, CF investigators both internationally recognized in their respective areas of clinical research and bacterial pathogenesis. They will be supported by other key leadership: Samuel Miller MD, Professor of Medicine, Microbiology, Genome Sciences, and Immunology, Charles Frevert, DVM, ScD, Associate Professor in the Department of Comparative Medicine, Christopher Goss MD, MPH, Professor of Medicine and Pediatrics, and Pradeep Singh MD, Professor of Medicine. The center will consist of an Administrative Core (Ramsey and Greenberg, Directors) and four biomedical cores, Microbiology (Greenberg, Director), Genomics (Miller, Director), Host Response (Frevert, Director) and Clinical Translational (Christopher Goss and Ramsey, Directors). The core centers will operate a Pilot and Feasibility (P&F) program led by Dr. Pradeep Singh. Three newly approved P&F projects are included in the current proposal chosen through a competitive process and approved by the Internal Advisory Board. During the funding period, the core center will focus on development of several novel therapeutic approaches to improve overall health for patients with CF.
The UW CFRTC focuses its research on developing new and improved treatments for patients with Cystic Fibrosis. The Center has a long history of strong partnerships between laboratory and clinically based scientists working together to take observations from the laboratory and transforming these findings into better drugs to treat the nutritional, metabolic and lung aspects of this fatal genetic disease. The Clinical and Microbiology Cores also have a well-established history of working with scientists across the world to further the successful development of new therapies, in particular antibiotic treatments.
|Matamouros, Susana; Hayden, Hillary S; Hager, Kyle R et al. (2018) Adaptation of commensal proliferating Escherichia coli to the intestinal tract of young children with cystic fibrosis. Proc Natl Acad Sci U S A 115:1605-1610|
|Heltshe, Sonya L; Taylor-Cousar, Jennifer L (2018) Let's talk about sex: Behaviors, experience and health care utilization in young women with CF. J Cyst Fibros 17:5-6|
|Ding, Fengming; Oinuma, Ken-Ichi; Smalley, Nicole E et al. (2018) The Pseudomonas aeruginosa Orphan Quorum Sensing Signal Receptor QscR Regulates Global Quorum Sensing Gene Expression by Activating a Single Linked Operon. MBio 9:|
|Gelfond, Daniel; Heltshe, Sonya L; Skalland, Michelle et al. (2018) Pancreatic Enzyme Replacement Therapy Use in Infants With Cystic Fibrosis Diagnosed by Newborn Screening. J Pediatr Gastroenterol Nutr 66:657-663|
|Hobler, Mara R; Engelberg, Ruth A; Curtis, J Randall et al. (2018) Exploring Opportunities for Primary Outpatient Palliative Care for Adults with Cystic Fibrosis: A Mixed-Methods Study of Patients' Needs. J Palliat Med 21:513-521|
|Hull, Rebecca L; Gibson, Ronald L; McNamara, Sharon et al. (2018) Islet Interleukin-1? Immunoreactivity Is an Early Feature of Cystic Fibrosis That May Contribute to ?-Cell Failure. Diabetes Care 41:823-830|
|Heltshe, S L; Khan, U; Beckett, V et al. (2018) Longitudinal development of initial, chronic and mucoid Pseudomonas aeruginosa infection in young children with cystic fibrosis. J Cyst Fibros 17:341-347|
|Irons, Jessica; Hodge-Hanson, Kelsey M; Downs, Diana M (2018) PA5339, a RidA Homolog, Is Required for Full Growth in Pseudomonas aeruginosa. J Bacteriol 200:|
|Klose, Alexander D; Paragas, Neal (2018) Automated quantification of bioluminescence images. Nat Commun 9:4262|
|Roch, Melanie; Varela, Maria Celeste; Taglialegna, Agustina et al. (2018) Activity of Telavancin against Staphylococcus aureus Isolates, Including Those with Decreased Susceptibility to Ceftaroline, from Cystic Fibrosis Patients. Antimicrob Agents Chemother 62:|
Showing the most recent 10 out of 222 publications